This research matters to people diagnosed with early-stage breast cancer, particularly those with small tumors. The standard treatment for these patients often includes a procedure called a sentinel lymph node biopsy (SLNB). This surgery checks if cancer has spread to nearby lymph nodes under the arm. However, the procedure can have side effects like pain, swelling, and limited arm movement. Researchers are asking if this biopsy is always necessary, especially for patients with a very low chance of having cancer in their lymph nodes. If it could be safely skipped, many patients might avoid surgery and its potential complications.
The study, called the NAUTILUS trial, is a randomized controlled trial (RCT), which is considered a strong type of medical study. It enrolled 1,734 patients with early-stage breast cancer (clinical stage T1-2, N0). This means their tumors were relatively small (5 cm or less) and doctors did not feel any cancer in the lymph nodes during an exam. The patients were randomly assigned to one of two groups: one group received the standard sentinel lymph node biopsy, and the other group did not receive the biopsy. This report does not tell us the results of comparing those two groups. Instead, it describes the patients at the start of the trial and what was found in the patients who did get the biopsy.
The key finding from this initial report comes from the group of patients who received the lymph node biopsy. Among these patients, 11.2% were found to have cancer cells in their axillary (underarm) lymph nodes. The report breaks this down further by tumor size. For tumors that were 1.0 centimeter or smaller, 7.0% of patients had lymph node involvement. For tumors larger than 1.0 cm but 2.0 cm or smaller, the rate was 12.8%. For tumors larger than 2.0 cm but up to 5.0 cm, the rate was 17.2%. In simple terms, as the tumor size increased, so did the chance of finding cancer in the lymph nodes. The median age of patients in the whole study was 55 years, and 40.1% were premenopausal. About 14% of patients had tumors in the pT2 size category (larger than 2 cm but not more than 5 cm).
This report does not discuss safety concerns or side effects. The main purpose here was to describe the patients and the lymph node findings in one group, not to report on the safety or effectiveness of skipping the biopsy. The comparative safety of omitting the sentinel node biopsy versus having it is a central question of the full trial, but those results are not part of this publication.
It is very important not to overreact to this single report. This is not the final result of the trial. It is a snapshot of the patients at the beginning and what was found in the lymph nodes of one group. The most critical information—whether patients who skipped the biopsy had similar long-term outcomes to those who had it—is still being collected and analyzed. The report itself states that the 'impact of SLNB omission' is an expectation, not a finding. We also do not know how long patients have been followed in this trial, which is crucial for understanding cancer recurrence. The results should be viewed as preliminary background data.
For patients right now, this study does not change current medical practice. The sentinel lymph node biopsy remains a standard part of care for many people with early-stage breast cancer. The NAUTILUS trial is ongoing work that may, in the future, help doctors identify a subgroup of patients for whom this procedure could be safely avoided. Patients should discuss the risks and benefits of all their treatment options, including lymph node surgery, with their oncology team. The final results of this and similar trials are needed before any recommendations can be made about routinely omitting this biopsy.
